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Health Insurance Service of Korea. All costs were measured in Korean won (KRW) and 
converted to US dollars (USD) using 2014 official exchange rate (1USD= 1,053.22KRW). 
Discount rate of 5% was applied to cost and effectiveness. Results: Based on com-
plete cytogenetic response rates at 12 month, Imatinib ($277,971) was less costly 
than Dasatinib ($388,232) and Nilotinib ($445,548). Life-year gains of Dasatinib (15.18 
LYs), were superior to other TKIs (Imatinib: 14.52 LYs, Nilotinib: 15.13 LYs), but ICER 
was $167,010 per LYs which far exceeds current willingness to pay level ($28,484) 
in Korea. Applying major molecular response rates at 12 month, the most effec-
tive strategy was Nilotinib ($416,513, 14.76 LYs), but its cost was the highest among 
others: Dasatinib ($365,602, 14.47 LYs) and Imatinib ($300,490, 13.8 LYs). The ICER of 
Dasatinib and Nilotinib was $98,483 and $170,431 per LYs respectively compared to 
Imatinib. ConClusions: Given the current willingness to pay level of $28,959 in 
Korean setting, Imatinib (400 mg) was found out to be the most cost-effective strategy 
compared to Dasatinib (100mg) and Nilotinib (300 mg).
PCN161
Cost-EffECtivENEss of DirECtly MailED fobt Kits to PrEvious 
rEsPoNDErs bEiNg rECallED for sCrEENiNg
Mittmann N1, Hassan S2, Patel J1, Tinmouth J1
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Sunnybrook Research Institute, 
Toronto, ON, Canada
objeCtives: To conduct a cost-effectiveness analysis to evaluate whether the addi-
tion of a fecal occult blood test (FOBT) kit to a mailed invitation for recall compared 
to a mailed invitation for recall alone increases participation among patients who 
had responded previously to a mailed invitation in screening for colorectal cancer 
(CRC). Methods: The perspective of the analysis will be that of the cancer agency 
in Ontario, Canada. Eligible patients (responders to the initial pilot study invita-
tion, FOBT negative, and now due for repeat screening) from 61 physicians were 
randomly allocated to one of the two interventions: (1) Mailed FOBT kit and mailed 
invitation for recall from their family physician (intervention group) OR (2) mailed 
invitation alone for recall (control group). Health system and program resources and 
costs associated with each group will be identified and quantified. Resources will 
be stratified into fixed costs (initial set-up costs including document development, 
programming for ongoing maintenance, etc.), variable or recurrent costs (costs of 
the kit, administrative costs, physician visits etc.) and staff costs (call centre sup-
port personnel and business analyst). Results: There are a total of 431 patients in 
the intervention group and 452 patients in the control group. Overall costs for each 
group will be determined, and the cost per patient will be reported. Cost drivers 
will be identified by conducting a series of univariate sensitivity analyses, including 
reducing the cost of the kit and using different assumptions for kit wastage. The 
results will show whether the addition of the FOBT kit to the mailed invitation is 
cost effective when compared to a mailed invitation only. ConClusions: This cost 
effectiveness analysis will help in determining effective strategies for screening 
programs that are needed to reduce CRC mortality at a population level.
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objeCtives: To assess the clinical and cost effectiveness of mammography for 
breast cancer screening in India Methods: A systematic literature search was 
conducted in all the available scientific databases - Cochrane library, MEDLINE, 
PUBMED Science Direct, EMBASE, SCOPUS and Google Scholar for relevant studies. 
We identified 31 studies and literature filter started by scanning titles; abstracts as 
well as the content of the articles according to Inclusion criteria; finally 12 studies 
were included in quantitative synthesis (Meta analysis). We estimated risk of bias 
using Cochrane collaborating guidelines. Results: Review Manager 5.2 was used 
to do the data analysis and results are expressed in legible diagrams, considering 
all 12 studies with data from 4047721 participants, Risk Ratio was calculated (RR): 
0.71 (95% confidence Interval, CI: 0.67, 0.75). ConClusions: Annual screening 
of female population above 30 years of age could reduce breast cancer associ-
ated mortality by 29% mainly due to early detection of breast cancer detection 
and subsequent early treatment pathways. The cost effectiveness is about Rs. 
19520/- per life year gained which is an excellent social return on investment on 
this technology.
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objeCtives: Evaluation of cost-effectiveness and cost-utility of afatinib in 
patients with non-small cell lung cancer (NSCLC) with deletion in 19th exon of epi-
dermal growth factor receptor (EGFR) gene in 1st-line therapy. Methods: Markov 
modeling was implemented to simulate clinical and economical outcomes of dif-
ferent strategies in treatment of naïve patients with NSCLC over 18 years old based 
on results of randomized clinical trials LUX-Lung 3 and LUX-Lung 6. Direct medical 
costs were considered. The time horizon of the analysis – 10 years. Compared 
drugs: afatinib, erlotinib, gefitinib and combination cisplatin/pemetrexed. Results 
were expressed in terms of quality-adjusted life years (QALY), life years (LY) gained 
and ICER (QALY). Results: Afatinib used as 1st-line treatment in patients with 
inform this model are US-specific and would require adaptation to be generalizable 
elsewhere. Depending on the threshold used by the decision maker, RAM+DOC 
may be a cost-effective option for the overall and nonsquamous NSCLC population.
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objeCtives: Abiraterone (ABI) and enzalutamide (ENZ) have been recently approved 
for the treatment of docetaxel (DOC)-naïve metastatic castration-resistant prostate 
cancer (mCRPC) but the cost-effectiveness associated with sequencing of these 
agents remains unclear. The objective of this study was to compare the efficacy 
and drug costs of different treatment sequences considering the loss of efficacy 
associated to subsequent treatments in mCRPC patients. Methods: Median overall 
survival (OS) and costs were estimated for the following sequences: (A) ABI-DOC-
CBZ; (B) ABI-DOC-ENZ; (C) ENZ-DOC-CBZ and (D) ENZ-DOC-ABI. OS and duration 
of treatment (DoT) estimates were based on data from clinical trials and adjusted 
according to literature review and expert clinical opinion, to account for potential 
efficacy loss after ABI or ENZ exposure as follows: DOC -10%; CBZ -10%; ENZ -40%; 
ABI -50%. The cost analysis included only drug costs and was undertaken from the 
perspective of the Spanish National Healthcare System. Incremental cost-effective-
ness ratios (ICERs) were calculated in terms of cost per life year gained (LYG) for 
the following comparisons: A-vs-B and C-vs-D. Uncertainties around efficacy and 
DoT assumptions were explored in a sensitivity analysis. Results: In the base 
case scenario, median OS estimates for patients treated with sequences A, B, C and 
D were 40.1, 37.5, 34.8 and 29.1 months, with respective costs of € 68,967, € 62,228, 
€ 60,766 and € 50,952. The ICERs were € 31,712/LYG for A vs B and € 20,697/LYG for C 
vs D. When reduction rates were applied only to OS but were not considered their 
influence on DoT, treatment sequences containing third-line CBZ were dominant vs 
sequences containing ENZ or ABI. ConClusions: Sequences containing third-line 
CBZ were more effective than sequences containing third-line ABI or ENZ. Third-line 
CBZ after ABI-DOC or after ENZ-DOC could be considered as cost-effective compared 
to third-line ABI or ENZ.
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objeCtives: To evaluate the cost-effectiveness of regorafenib compared to 
the standard of care (SoC), in the treatment of metastatic colorectal cancer in 
previously treated patients. Methods: A cohort partition model demonstrating the 
progression of mCRC patients towards death and evaluating clinical and economi-
cal outcomes was adapted to the Turkish setting. Event and mortality rates were 
derived from the CORRECT clinical trial. An expert panel, with the participation of 
experts in colorectal cancer, was established for the adaptation of clinical data to 
Turkish practice. The analysis was undertaken from payer perspective. The time 
horizon was taken as life time period. Costs of each health state included year 2015 
local costs of medications, monitoring and events (TL/EUR currency rate was set 
at 2.9274; mid 2015). Incremental cost effectiveness ratios (ICER) per life year (LY) 
were calculated. Willingness-to-pay (WTP) threshold was set to two times of the 
local gross domestic product per capita per life years saved (adapted from World 
Health Organization definition) and was calculated as 18,481EUR. One-way sensi-
tivity analyses were conducted to test the robustness of the model. Results: The 
total cost of regorafenib was 2,173EUR higher compared to SoC. Regorafenib was 
associated with increment of 0.153 LYs, leading to an ICER of 14,188EUR/LY gained. 
Life years gained were 0.215 and 0.221 years in patients with wild type K-ras muta-
tion and patients with less than 4 lines of treatment, respectively. Accordingly, ICER 
values were lower (10,280EUR and 8,308EUR) than overall group in these subgroups. 
Sensitivity analyses showed that the cost-effectiveness results are fairly insensitive 
to most inputs. ConClusions: Regorafenib, given its improvement in progression 
free survival and overall survival, and ICER values below WTP threshold, is suggested 
to be a cost-effective alternative in the treatment of metastatic colorectal cancer in 
previously treated patients in Turkey.
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objeCtives: This study aims to evaluate cost effectiveness of currently available first-
line TKIs, Dasatinib (100mg), Nilotinib (600 mg) and Imatinib (400mg), in treatment of 
newly diagnosed CML patients in Korea. Methods: We developed a Markov model 
model composed of four health states: response in chronic-phase (CP), no-response 
in CP, accelerated or blastic phase (AP/BP) and Death. Progression rate to AP/BP is 
assumed to be dependent on the presence of cytogenetic or molecular response to 
TKI at 12 month. Clinical effectiveness were obtained from DASISION and ENESTnd 
trials. In terms of cost, only direct medical costs (e.g. outpatient, hospitalisation and 
medication costs) with 5% of patient copayment were included into the study. Average 
medical cost of CML patients were calculated using claims data from the National 
